Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company specializing in Antibody Drug Conjugates (ADCs) for cancer therapy, announced that its shareholders approved all management proposals with a large majority at the company's ordinary virtual Annual General Meeting held on June 23, 2026. The approval rates ranged from 98.67% to 98.72% across all agenda items, reflecting strong shareholder support for the company's direction.
Key resolutions included the formal approval of the actions of the Management Board and Supervisory Board for the 2024/2025 financial year, the appointment of auditors for the 2025/2026 financial year, and the approval of the remuneration report for the Management Board. Notably, shareholders elected Mr. Jack Yefei Ling as a new member of the Supervisory Board. Additionally, a resolution was passed to amend the Articles of Association to reduce the size of the Supervisory Board from seven to five members. The attendance, including postal votes, corresponded to 80.55% of the current capital stock, indicating high shareholder engagement.
Heidelberg Pharma is known for pioneering cancer therapies using Amanitin, a toxin derived from the green death cap mushroom. The company's proprietary ATAC technology utilizes Amanitin-based ADCs, offering a novel therapeutic modality. The lead candidate, HDP-101 (INN: pamlectabart tismanitin), targets BCMA for multiple myeloma and has received Orphan Drug Designation and Fast Track Designation from the FDA. Another candidate, HDP-102, is in clinical development for Non-Hodgkin Lymphoma. HDP-103 and HDP-104, targeting metastatic castration-resistant prostate cancer and gastrointestinal tumors such as colorectal cancer, respectively, have completed preclinical development and are available for partnering.
For more details on the Annual General Meeting, including voting results, visit the company's AGM page at https://heidelberg-pharma.com/en/agm. Heidelberg Pharma is based in Ladenburg, Germany, and is listed on the Frankfurt Stock Exchange. More information is available at www.heidelberg-pharma.com.
